Talem preclinical experts match high value targets to fully vetted, premium antibody programs. Catapult your discovery project past the launch phase and accelerate to clinical success. Select from key targets for multiple indications, for licensing or co-development, including:
• Discovery, preclinical and IND-enabling antibody programs
• A broad range of indications: immuno-oncology, oncology, COVID-19, ophthalmology, inflammation, immunology, and infectious, rare/neglected, autoimmune, and heart diseases
• Co-development of Talem internal, de novo and partner-specific programs